Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines – Business Wire

By Somatic Stem Cells

SAN DIEGO--(BUSINESS WIRE)--Allele Biotechnology and Pharmaceuticals, Inc. (President and CEO: Jiwu Wang, Ph.D., Allele), a San Diego-based private company, and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas), through its Massachusetts-based subsidiary Astellas Institute for Regenerative Medicine (AIRM), entered into a licensing agreement to expand Astellas access to Alleles induced pluripotent stem cell (iPSC) technologies for various cell therapy programs.

Astellas, one of the largest pharmaceutical companies in Japan and already a leader in the development of cell-based therapeutics, has further dedicated to development of the field through its commitment to state-of-the-art iPS cell generation, modification, and manufacturing. iPSC lines can differentiate into all somatic tissue types, enabling a wide variety of therapeutic applications. The field of iPSC-derived cells has seen dramatic growth in clinical trials recently--the majority of the ~12 clinical trials around the world were initiated within the last 18 months and many more are upcoming.

Allele has been developing its core strength in reprogramming somatic cells into iPSCs with granted patents and the first commercial cGMP system it developed over the past 10 years. Allele also engages in more than a dozen different human tissue derivation activities through its own R&D efforts for internal programs and partnerships. To realize the unparalleled potential of iPSC, Alleles researchers and cGMP team are committed to setting up and validating cell assays for product quality control, genome analysis pipelines, closed-system automation for reprogramming, and machine learning in iPSC-related fields.

Under the terms of the new license agreement, Astellas will pay Allele upfront and milestones, product-based royalties, and potentially manufacture fees.

About AlleleAllele Biotechnology and Pharmaceuticals was founded in 1999. In 2015, the company completed an 18,000 square foot state-of-the-art facility in San Diego for the production of GMP-grade human iPSC lines. The facility also supports the production of tissue-specific cells differentiated from these iPSCs, including pancreatic beta cells, neural progenitor cells, and cardiomyocytes.

View original post here:
Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines - Business Wire

SVHI PRP Therapy Announces New Website Focused on PRP for Hair Loss in the San Francisco Bay Area – Benzinga

By Platelet Rich Plasma Injections

FOSTER CITY, Calif., Jan. 17, 2020 /PRNewswire-PRWeb/ --SHVI PRP Therapy, the leader in innovative hair loss treatments based on PRP (Platelet Rich Plasma) at https://svhi-prp.com/, is proud to announce a new website. The new website is a "microsite," focused specifically at the use of PRP to mitigate hair loss. Many Bay Area consumers are open to cutting edge technologies, and PRP is one option in their hair loss journey.

"PRP therapy for hair loss is an innovative option for many Bay Area patients," explained Miguel Canales, surgeon and founder of SVHI PRP therapy. "Even more important, a patient who seeks out a consultation with me on hair loss will be able to review the entire range of options from PRP therapy to hair loss to hair transplantation. I will work with each patient to create the best treatment program for their hair loss needs."

Persons who would like to learn more about the company can visit the new website. In particular, they can focus on the page specific to PRP therapy can visit https://svhi-prp.com/prp-therapy/. Another option is to read the FAQ (Frequently Asked Questions) document at https://svhi-prp.com/faq/. That document explains as follows. Hair thinning in women, which affects nearly 40 million American women, is mainly due to heredity and can start any time after puberty. However, we also know that female pattern hair loss can be strongly influenced by age, nutrition, stress, surgery, medications, illness, social/lifestyle factors, hair care and more. As hair follicles weaken and stop producing hair, hair loss occurs. Remarkably, PRP for hair loss can impact the hair itself, often resulting in hair rejuvenation.

PRP or Platelet Rich Plasma for hair loss is an in-office, non-surgical, treatment derived from the patient's own blood that can be performed in about an hour. After the area of concern is identified, evaluated and measured, standardized medical photos are taken in the photo suite. Special gentle and sterile techniques and equipment are used to separate and concentrate the platelets and plasma from a small sample of peripheral blood. PRP contains growth factors and cytokines that have been shown to be responsible for stimulating and enhancing hair follicle function. The scalp is prepared with antiseptic solution and anesthetic (a "ring block," not simply local anesthetic gel) is used to completely numb the scalp. Small injections of the PRP deliver the powerful platelet-derived growth factors into the skin at the level of the weak follicles. Electronic, mechanical microneedling is performed.

ABOUT SVHI PRP THERAPY

SVHI PRP Therapy is a Bay Area company based in Foster City, California, that offers PRP for hair loss to clients from San Francisco to San Mateo, Palo Alto to Redwood City, Redwood City to Burlingame and beyond. Clients who are suffering from hair loss and are seeking innovative therapy come to SVHI PRP Therapy to explore their options, including PRP therapy for hair loss. The company offers a no obligation consultation on hair loss with Dr. Miguel Canales, a recognized specialist in the hair loss industry including hair transplantation.

SOURCE SVHI PRP Therapy

Here is the original post:
SVHI PRP Therapy Announces New Website Focused on PRP for Hair Loss in the San Francisco Bay Area - Benzinga

Learning to be relentless – The Daily Republic

By Stem Cell Doctors

Thats something 13-year-old Floyd Korzan learned the hard way when his father, Matt, was diagnosed with acute myeloid leukemia, a highly-deadly form of blood cancer, after he fell ill on a family hiking trip in the Black Hills in 2012.

Matts fight against the disease has since taken the Mitchell family on a journey of frightening lows and celebratory highs and led Floyd to start Relentless Pledge, a non-profit organization that encourages patients to be as relentless as his father as they fight to achieve the goal of overcoming cancer.

We basically have two goals. The first one is to inspire others to overcome obstacles and dream their dreams. And the second part of the goal is to give a Relentless wristband to every cancer patient in Mitchell, our hometown, and eventually, if we get big enough, South Dakota and the United States, Floyd said in an interview with the Daily Republic.

Its a goal borne out of Floyds experience when he sat with his father at the Mayo Clinic in Rochester, Minnesota as he underwent treatments for the disease. Matt beat the leukemia once, but it later returned, a bad sign when associated with this particular kind of cancer. It went into remission again but returned again in 2017, and doctors were not hopeful.

With few options remaining, Matt agreed to a stem cell donation treatment that would use cells provided by his sister, Margaret, who happened to be a 100 percent match, injected into his system following an intense round of chemotherapy. The treatment was difficult, but after 8 million donor cells were circulated through his system, the doctors began to see good results.

Little by little, I came back, Matt said. After 30 days, they did a bone marrow biopsy that showed no evidence of leukemia whatsoever. They did another one at the end of the year, still no evidence of leukemia. They did one at the two-year mark, still no evidence of leukemia.

Visitors to relentlesspledge.org can nominate individuals to receive Relentless wristbands, which remind people to stay the course when attempting to achieve their goals. (Erik Kaufman / Republic)

Floyd recounted the scary days of his dads fight in an essay posted on his website relentlesspledge.org. He asked his father at the time how he could be as strong as he was even as he suffered from the disease and the side effects of his treatment. Matts response was that there may be times in life when the only person left who believes in you is you, and in those times, you must be relentless in order to make it through.

Floyd had found his own inspiration in his fathers fight, and he wanted to spread that inspiration to others who were suffering. Normally a private person, Matt agreed to share his story with the public and helped his son form Relentless Pledge, which encourages people to live life to the limit, to dare, to dream, and be relentless in overcoming challenges.

Visitors to the website can take the pledge, as well as nominate individuals to receive one of the symbols of the organization: a wristband bearing the word Relentless. Visitors can also order wristbands for themselves, family members, friends as well as cancer patients.

The goal is to spread the message of hope to every cancer patient in America, Floyd said. He has shipped orders of wristbands to 26 states around the country and three continents already, and the pair plan to pass out the wristbands to people in the leukemia ward at the Mayo Clinic, where Matt returns periodically for continued treatments. More wristbands will be given out at the Avera Cancer Center in Mitchell.

In total, they estimate theyve given out about 400 of them so far. And the campaign is officially less than two weeks old.

It seemed to strike a chord with people, Matt said.

As the young program grows, Floyd said the organization could expand to include more than just cancer patients in its message. There are others who are trying to accomplish goals, as well, such as public servants or community-minded individuals.

Its not all about cancer. Now were looking at giving them out to local heroes," Floyd said. "So far, weve given them to local firefighters and the librarians at the Mitchell Public Library, and were thinking about the police department."

Floyd hopes Relentless Pledge continues to grow. He is eyeing expanding the Relentless line to include t-shirts that would promote the Relentless Pledge, but for now he is concentrating on fulfilling orders for the wristbands and getting them in the hands of people who need inspiration.

I have big dreams in the future where this organization could expand to have a full line of accessories, Floyd said. Relentless gear.

Matt said he is recovering a little more each day, and hes grateful. Hes been able to throw the ball around in the yard with Floyd again, and he is working to become stronger as he continues his recovery. He said hes grateful for the love and support of Floyd as well as his wife Bam and other children Alexis, Cassidy, Hailey and Jackson. Hes thankful for doctors like Kebede Begna and Lucio Margallo, both of whom Matt described as relentless in helping him fight for his health.

And hes happy to help Floyd spread the message of hope through Relentless Pledge, he said.

I think its great. I think its a noble project, and I think its good for Floyd. Of all the ways a teenager can spend their time, this is pretty solid, Matt said.

Floyd said he plans to continue his work with the organization well into the future. He has a little over four years left before he leaves for college, and with that time he plans to do everything he can to remind those who are struggling to remain relentless.

One Relentless wristband at a time.

The next step is spreading the word, Floyd said.

More:
Learning to be relentless - The Daily Republic

Here’s Why Stemline Therapeutics Dropped Today – Motley Fool

By Stem Cell Doctors

What happened

Shares of Stemline Therapeutics (NASDAQ:STML) were down 34% at 11:42 a.m. EST after the company released disappointing preliminary fourth-quarter results.

The biotech estimates that it sold $11.8 million worth of Elzonris, a drug that treats blastic plasmacytoid dendritic cell neoplasm (BPDCN), a type of blood cancer. That's lower than the $13.1 million Stemline Therapeutics sold in the third quarter -- when, as the company noted, the number of new patients on the drug increased by over 20% quarter over quarter.

Management didn't give much color on the reason for the quarter-over-quarter decline in the press release, but the company has noted in the past that BPDCN is often misdiagnosed, and it was working with doctors to increase the speed and accuracy of diagnoses. Management will likely update investors on the progress and reason for the sales slowdown during the company's presentation at the J.P. Morgan Healthcare Conference on Wednesday.

Image source: Getty Images.

The slowdown in launch trajectory is certainly disappointing, but Stemline Therapeutics has plenty of opportunities to turn things around. Elzonris is under review by EU regulators, setting up a likely approval this year.

Further down the line, there's potential to expand Elzonris into other blood cancers; the company is currently testing the drug in three different blood cancers -- chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia -- with clinical trial data in all three expected this year. There's also potential to move Elzonris into the maintenance setting for patients treating their BPDCN through a stem cell transplant; initial data in that setting is expected this quarter.

Continued here:
Here's Why Stemline Therapeutics Dropped Today - Motley Fool

Medics key to spotting signs of child abuse, Abu Dhabi conference hears – The National

By Stem Cell Doctors

The crucial need to spot the telltale signs of child abuse was high on the agenda as a global medical conference got under way in Abu Dhabi on Thursday.

Experts said doctors and nurses were well placed to uncover any early child abuse indicators, but must be clear in their diagnosis as bruising is common and can often indicate serious illnesses such as leukaemia.

The vital topic was put under the microscope during the opening sessions of the 14th Seha International Paediatric Conference at the Rosewood hotel on Al Maryah Island.

Doctors and other healthcare professionals will assess the latest developments in child healthcare during the three-day conference.

It can be the most amazing family in the world, but abuse in the home can be happening and doctors can quickly determine that with a proper physical assessment, said Dr Leslie Lehman, clinical director of paediatric stem cell transplants at Boston Childrens Hospital in the US.

A detailed history and physical exam of a child can determine the cause of bruising and rule out abuse.

Most bruises in childhood are result of minor environmental interactions.

If doctors are still unsure of the cause of bruising, a paediatric haematologist should be consulted.

Researchers also discussed breakthroughs in how to spot early signs of sepsis, paediatric hypertension, and bone and joint infections.

Delegates from some of the leading international care facilities attended the event to share their most recent findings and research.

They included experts from the Childrens Hospital in Philadelphia, the Cincinnati Childrens Hospital, Boston Childrens Hospital, National Childrens Hospital in Washington and Londons Great Ormond Street Hospital.

Abu Dhabi Health Services Company, the UAEs largest healthcare network, is hosting the 14th edition of a conference that has become one of the most prominent in the field, providing significant advantages to professionals who serve children in the UAE and the wider region.

Sehas priority is to offer children with services and treatment methods that match, if not exceed, the highest international standards, said Dr Elsadeg Mohamed Sharif, a consultant paediatrician at Al Ain Hospital.

It is dedicated to utilising the available technology and expertise worldwide to deliver on that promise.

Updated: January 16, 2020 03:05 PM

Read more:
Medics key to spotting signs of child abuse, Abu Dhabi conference hears - The National

Smart Group & A4M Concluded their First India Conference 2020 – NewsPatrolling

By Stem Cell Doctors

Smart Group & American Academy of Anti-Aging Medicine have successfully concluded their first conference featuring esteemed speakers, experts, clinicians, and researchers in the field of Integrative and Functional Medicine.

New Delhi 18 January 2020 On Saturday, January 18th, 2020, the Smart Group in partnership with A4M together held their 1st India Conference at the Hyatt Regency, New Delhi. The two-day conference featured esteemed speakers, celebrated doctors and learned professionals in the field of preventive, integrative and traditional medicine from India and across the globe.

Addressed by some of the worlds leading faculty in preventive healthcare, this groundbreaking event was attended by more than 300 doctors and featured the most cutting edge and futurists innovations in healthcare.The guest speakers at the conference were globally renowned scholars who have been leading integrative medicine globally and key leaders of the$4trillion global wellness industry which is due to swell to$30trillion.

The audience had a chance to listen to globally renowned speakers like Dr Andrew Heyman (MD, MHSA); Dr Pamela Smith (MD, MPH, MS); Dr Daniyar Jumaniyazov (MD, PhD); Dr Graham Simpson (MD); Dr Brian Delaney (PHD) and Indian health leaders like Deepak A V Chaturvedi (MD), endocrinologist from Mumbai; Alok Sharma, President, Stem Cell Society India; Dr BS Rajput Vice President , Stem Cell Society India ; functional medicine experts like celebrity nutritionist, Dr Anjali Hooda amongst others.

A series of sessions as conducted by renowned industry experts, featured new age topics including intermittent fasting, regenerative medicine, autoimmunity, biochemical detox, and sub-fertile male amongst others, all of which have taken urban India by storm and are being increasingly endorsed by celebrities from Bollywood, sports and even politics. A key feature of the conference was the scientifically curated exhibition featuring nutraceutical providers, companies in cellular regeneration & gene testing, healthcare equipments enabled by artificial intelligence. Healthcare stalwarts like Dabur and Apollo showcased their futuristic vision for healthcare in India

Keeping with the futuristic theme of the conference, Dr M (BK Modi) Founder-Chairman, Smart Group, addressed the audience via a video conference. Detailing his own experience with stem cells, he said, I am very glad that doctors in India are taking a keen interest in preventive health. Cellular therapy has personally given me a renewed zeal and has enabled me to pursue my passion despite my age. I wish more people discover the benefits of preventive health, and can lead happy & healthy lives, beyond 100.

The thought was echoed by Ms Preeti Malhotra (Chairman, Smart Bharat and President Organising committee, Smart A4M India conference, Medicine has taken an exponential leap this century. Preventive health has had a profound effect on human longevity, awareness, mental wellbeing. There are researches claiming that children born in the coming years may live for upto a 1000 years, this has a profound effect on social relations, economies and the future of a nation. I am very happy that we were a able to bring A4M into India to initiate this conversation, much needed in a country like ours.

Given the resounding success of Smart Group & A4Ms 1st India Conferences Day 1, its hoped that the Day 2 shall offer even greater wisdom to the participants by helping them improve and the lead the community into the age of greater awareness.

Read more from the original source:
Smart Group & A4M Concluded their First India Conference 2020 - NewsPatrolling

Introducing Generate Life Sciences – A First-Of-Its-Kind Company Focused On Helping Grow And Protect Healthy Families – Yahoo Finance

By Stem Cell Medicine

With over 40+ years of leadership and expertise in reproductive, newborn stem cell, and genetic services, Generate has already helped grow and protect nearly 1 million families around the world

LOS ANGELES, Jan. 13, 2020 /PRNewswire/ --California Cryobank Life Sciences today announced the launch of its new company brand - Generate Life Sciences (Generate). The rebranding follows the joining of California Cryobank and CBR (Cord Blood Registry) in August 2018 and represents the company's mission to become a life sciences platform that helps grow and protect healthy families through reproductive, newborn stem cell, genetic testing, medical device and healthcare technology services.

Generate serves families from preconception to post-birth throughout the significant and highly personalized journey of building a family and protecting their children's health. Built upon the pillars of innovation, access, and connection, Generate has already helped grow and protect nearly 1 million families around the world.

Our legacy brands CBR, California Cryobank, and Donor Egg Bank USA are pioneering leaders in their respective fields and continue to set industry standards for innovation, scientific excellence, and customer focus. Generate is furthering the impact of this life sciences platform with the addition of advanced pediatric genetic testing, US distribution of reproductive medical devices and proprietary healthcare technology through the respective brands ReadyGen (pediatric genetic screening powered by Sema4), Kitazato USA (medical device distribution), and Donor Application (proprietary software for reproductive clinics).

"Our brands are leaders in each of their categories; as a life sciences platform, we are uniquely positioned to give clients access to the full range of expertise and services needed to create and support healthy families," said Richard Jennings, Chief Executive Officer. "Generate helps its clients realize their dreams of having a baby and provides access to scientific innovations in stem cells and genetic services that improve the lives of families around the world."

With the substantial growth in single parenting by choice and LGBTQ+ family building, as well as a trend towards having children later in life, Generate's reproductive health services have never been in higher demand. Similarly, advances in stem cell therapies and research into regenerative medicine have emphasized the importance and increased the awareness and interest in storing newborn stem cells with CBR.

"Generate Life Sciences is positioned to play an increasingly important role in protecting families as regenerative medicine and new genetic testing platforms open the door to the future of personalized medical treatments," said Jaime Shamonki, MD, Chief Medical Officer. "Uniting key elements of the family-building experience under Generate will give our clients peace of mind, convenient access, and exceptional support throughout this significant time in their lives. This organization has collectively helped create nearly 100,000 families and provides access to invaluable long-term health benefits to almost a million more. For us, Generate represents more than just good business; it is advancing scientific innovations that help the future of humanity."

"The journey to parenthood has evolved over the years, but the end goal is the same people want to have children and they want to keep them safe and healthy. In the modern age, we have advanced the science and technology available to help individuals grow their families and be more proactive in planning for their future health," said Michael J. Levy, MD, IVF Director and Co-Founder, Shady Grove Fertility. "That is where Generate Life Sciences becomes a trusted partner for clients from pre-conception through post-birth. From donor egg and donor sperm to newborn stem cell services and genetic testing, Generate is there every step of the way. And the possibilities are endless."

"Generate Life Sciences made our dream of becoming parents a reality. From helping us choose our amazing California Cryobank sperm donor for our twin girls, to rushing a CBR cord blood collection kit for our son when my wife went into early labor, they have always gone above and beyond to help. We look to Generate as a trustworthy partner we can rely on for these very personal and private moments in our lives," said Sharon Kochlany & Vanessa Colimorio, customers of Generate.

Story continues

Generate Life Sciences BrandsGenerate Life Sciences is a company of established, trustworthy brands founded and grown over 40 years by experts in reproductive medicine, newborn stem cell services, and genetics. Those brands include:

Newborn Stem Cell Services CBR (Cord Blood Registry): CBR has stored newborn stem cells (stem cells collected from cord blood and cord tissue) for almost 30 years.

Reproductive ServicesCalifornia Cryobank Donor Sperm Bank:California Cryobank is a pioneer and industry leader in donor sperm banking, offering the most rigorously screened donors, largest selection, and scientific expertise for more than 40 years.

Donor Egg Bank USA:Donor Egg Bank is a true leader in its category, maintaining the highest clinical pregnancy rate in the industry, while growing the largest frozen donor egg program in the United States.

NW Cryobank:For over 30 years, NW Cryobank has been helping couples, single women, and the LGBTQ+ community create happy, healthy families.

Genetic Services ReadyGen:Powered by Sema4, ReadyGen is an innovative and advanced pediatric screening test that empowers parents to further protect their children by delivering clinically actionable and personalized health insights.

Medical Devices and Healthcare TechnologyKitazato USA:Kitazato USA by California Cryobank is the exclusive distributor of Kitazato products in the US, offering devices for human assisted reproductive medicine from the innovator of the Cryotop Method vitrification technique.

Donor Application: Proprietary software providingdonor screening and recipient matching services on a HIPAA compliant platform.

About Generate Life SciencesGenerate Life Sciences (Generate)is a life sciences company helping to grow and protect families through reproductive, newborn stem cell, genetic screening, medical device, and healthcare technology services. We serve families from preconception to post-birth. Our brands - CBR (Cord Blood Registry), California Cryobank Donor Sperm Bank, Donor Egg Bank USA, NW Cryobank, ReadyGen, Kitazato USA, and Donor Application are pioneering leaders, helping to grow and protect nearly 1 million families. Headquartered in Los Angeles, Generate operates facilities in Tucson, New York, Boston, Palo Alto, and Rockville, MD. Generate is a portfolio company of GI Partners, a private investment firm based in San Francisco.

Media ContactsMonica Rohledermedia@generatelifesciences.com847-606-1973

Between Life and Science is Opportunity

View original content to download multimedia:http://www.prnewswire.com/news-releases/introducing-generate-life-sciences--a-first-of-its-kind-company-focused-on-helping-grow-and-protect-healthy-families-300985444.html

SOURCE Generate Life Sciences

Read more here:
Introducing Generate Life Sciences - A First-Of-Its-Kind Company Focused On Helping Grow And Protect Healthy Families - Yahoo Finance

Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer – Yahoo Finance

By Stem Cell Medicine

CAMBRIDGE, Mass. and DALLAS, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (EDIT), a leading genome editing company, and Sandhill Therapeutics, Inc., a cellular immuno-oncology company, announced a strategic research collaboration, license, and option agreement to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture allogeneic engineered natural killer (NK) cells and non-alpha beta T cell medicines for the treatment of cancer.

This collaboration brings together Editas Medicines leading genome editing technology and Sandhills BINATE product process, a novel universal donor technology to extract, isolate, and expand NK cells and non-alpha beta T cells, to develop novel medicines for the treatment of solid tumor cancers.

We are excited to work with Sandhill, combining CRISPR-based genome editing with BINATE cells to accelerate the development of numerous, transformative medicines for people with cancer and improve patient outcomes, said Charles Albright, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. We continue to increase our commitment to oncology, and we believe our portfolio of multiple immune system cell types, including T cells, NK cells, and induced pluripotent stem cells (iPSCs), will be effective in making the next generation of allogeneic medicines to fight many common cancers.

The team at Editas Medicine has one of the most innovative technology platforms, and we look forward to combining our technologies to create new medicines for the treatment of cancer. Together, we are dedicated to transforming cellular immuno-oncology and developing new therapies, said Annemarie Moseley, M.D., Ph.D., Chief Executive Officer, Sandhill Therapeutics, Inc.

Under the terms of the agreement, Editas Medicine obtains an exclusive license to Sandhills technology to research, develop and commercialize immuno-oncology engineered cell medicines for solid tumors originating within a given area of the body and an option to expand such license to two additional areas. In return, Sandhill will receive an upfront payment, development and sales-based milestone payments, and royalties on sales of resulting Editas products.

RBC Capital Markets acted as exclusive financial advisor to Sandhill for the transaction.

About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit http://www.editasmedicine.com.

About Sandhill Therapeutics, Inc.Sandhill Therapeutics is a privately held, development stage cellular immunotherapy company dedicated to improving the lives of children and adults with cancer. Sandhills BINATE leverages dual innate cell synergy, resulting in a highly activated, readily available, universal off-the-shelf treatment for both solid tumors and blood cancers. Sandhills activated innate cell immunotherapy is generated by a cost-effective, feeder-free campaign manufacturing process. For more information, visitwww.sandhilltx.com.

Editas Medicine Forward-Looking Statements This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, target, should, would, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Editas Medicine may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Editas Medicines product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for Editas Medicines foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption Risk Factors included in Editas Medicines most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that Editas Medicine may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release representEditas Medicinesviews only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law,Editas Medicineexplicitly disclaims any obligation to update any forward-looking statements.

Story continues

See more here:
Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer - Yahoo Finance

Stem Cell Research: Uses, Types & Examples

By Stell Cell Research

Stem cells are undifferentiated, or blank, cells. This means theyre capable of developing into cells that serve numerous functions in different parts of the body. Most cells in the body are differentiated cells. These cells can only serve a specific purpose in a particular organ. For example, red blood cells are specifically designed to carry oxygen through the blood.

All humans start out as only one cell. This cell is called a zygote, or a fertilized egg. The zygote divides into two cells, then four cells, and so on. Eventually, the cells begin to differentiate, taking on a certain function in a part of the body. This process is called differentiation.

Stem cells are cells that havent differentiated yet. They have the ability to divide and make an indefinite number of copies of themselves. Other cells in the body can only replicate a limited number of times before they begin to break down. When a stem cell divides, it can either remain a stem cell or turn into a differentiated cell, such as a muscle cell or a red blood cell.

Since stem cells have the ability to turn into various other types of cells, scientists believe that they can be useful for treating and understanding diseases. According to the Mayo Clinic, stem cells can be used to:

There are several types of stem cells that can be used for different purposes.

Embryonic stem cells come from human embryos that are three to five days old. They are harvested during a process called in-vitro fertilization. This involves fertilizing an embryo in a laboratory instead of inside the female body. Embryonic stem cells are known as pluripotent stem cells. These cells can give rise to virtually any other type of cell in the body.

Adult stem cells have a misleading name, because they are also found in infants and children. These stem cells come from developed organs and tissues in the body. Theyre used by the body to repair and replace damaged tissue in the same area in which they are found.

For example, hematopoietic stem cells are a type of adult stem cell found in bone marrow. They make new red blood cells, white blood cells, and other types of blood cells. Doctors have been performing stem cell transplants, also known as bone marrow transplants, for decades using hematopoietic stem cells in order to treat certain types of cancer.

Adult stem cells cant differentiate into as many other types of cells as embryonic stem cells can.

Scientists have recently discovered how to turn adult stem cells into pluripotent stem cells. These new types of cells are called induced pluripotent stem cells (iPSCs). They can differentiate into all types of specialized cells in the body. This means they can potentially produce new cells for any organ or tissue. To create iPSCs, scientists genetically reprogram the adult stem cells so they behave like embryonic stem cells.

The breakthrough has created a way to de-differentiate the stem cells. This may make them more useful in understanding how diseases develop. Scientists are hoping that the cells can be made from someones own skin to treat a disease. This will help prevent the immune system from rejecting an organ transplant. Research is underway to find ways to produce iPSCs safely.

Cord blood stem cells are harvested from the umbilical cord after childbirth. They can be frozen in cell banks for use in the future. These cells have been successfully used to treat children with blood cancers, such as leukemia, and certain genetic blood disorders.

Stem cells have also been found in amniotic fluid. This is the fluid that surrounds a developing baby inside the mothers womb. However, more research is needed to help understand the potential uses of amniotic fluid stem cells.

Adult stem cells dont present any ethical problems. However, in recent years, there has been controversy surrounding the way human embryonic stem cells are obtained. During the process of harvesting embryotic stem cells, the embryo is destroyed. This raises ethical concerns for people who believe that the destruction of a fertilized embryo is morally wrong.

Opponents believe that an embryo is a living human being. They dont think the fertilized eggs should be used for research. They argue that the embryo should have the same rights as every other human and that these rights should be protected.

Supporters of stem cell research, on the other hand, believe that the embryos are not yet humans. They note that researchers receive consent from the donor couple whose eggs and sperm were used to create the embryo. Supporters also argue that the fertilized eggs created during in-vitro fertilization would be discarded anyway, so they might be put to better use for scientific research.

With the breakthrough discovery of iPSCs, there may be less of a need for human embryos in research. This may help ease the concerns of those who are against using embryos for medical research. However, if iPSCs have the potential to develop into a human embryo, researchers could theoretically create a clone of the donor. This presents another ethical issue to take into consideration. Many countries already have legislation in place that effectively bans human cloning.

In the United States, federal policy regarding stem cell research has evolved over time as different presidents have taken office. Its important to note that no federal regulation has ever explicitly banned stem cell research in the United States. Rather, regulations have placed restrictions on public funding and use. However, certain states have placed bans on the creation or destruction of human embryos for medical research.

In August 2001, former President George W. Bush approved a law that would provide federal funding for limited research on embryonic stem cells. However, such research had to fit the following criteria:

In March 2009, President Barack Obama revoked former President Bushs statement and released Executive Order 13505. The order removed the restrictions on federal funding for stem cell research. This allowed the National Institutes of Health (NIH) to begin funding research that uses embryonic stem cells. The NIH then published guidelines to establish the policy under which it would fund research. The guidelines were written to help make sure that all NIH-funded research on human stem cells is morally responsible and scientifically relevant.

Stem cell research is ongoing at universities, research institutions, and hospitals around the world. Researchers are currently focusing on finding ways to control how stem cells turn into other types of cells.

A primary goal of research on embryonic stem cells is to learn how undifferentiated stem cells turn into differentiated stem cells that form specific tissues and organs. Researchers are also interested in figuring out how to control this process of differentiation.

Over the years, scientists have developed methods to manipulate the stem cell process to create a particular cell type. This process is called directed differentiation. A recent studyalso discovered the first steps in how stem cells transform into brain cells and other types of cells. More research on this topic is ongoing.

If researchers can find a reliable way to direct the differentiation of embryonic stem cells, they may be able to use the cells to treat certain diseases. For example, by directing the embryonic stem cells to turn into insulin-producing cells, they may be able to transplant the cells into people with type 1 diabetes.

Other medical conditions that may potentially be treated with embryonic stem cells include:

Californias Stem Cell Agency provides a detailed list of the disease programs and clinical trials currently underway in stem cell research. Examples of such projects include:

Researchers are also using differentiated stem cells to test the safety and effectiveness of new medications. Testing drugs on human stem cells eliminates the need to test them on animals.

Stem cell research has the potential to have a significant impact on human health. However, there is some controversy around the development, usage, and destruction of human embryos. Scientists may be able to ease these concerns by using a new method that can turn adult stem cells into pluripotent stem cells, which can change into any cell type. This would eliminate the need for embryonic stem cells in research. Such breakthroughs show that much progress has been made in stem cell research. Despite these advancements, theres still a lot more to be done before scientists can create successful treatments through stem cell therapy.

Read the original post:
Stem Cell Research: Uses, Types & Examples

Stem Cell Assay Market expected to Witness a Sustainable Growth over 2016 2024 Dagoretti News – Dagoretti News

By Stell Cell Research

About global Stem Cell Assay market

The latest global Stem Cell Assay market study is an in-depth and professional assessment of the current situation of the global Stem Cell Assay industry, including market size, revenue, pricing, trends, and future prospects. According to the report, the global Stem Cell Assay market pegged a value of ~US$ xx Mn/Bn in 2018 and is expected to progress at a CAGR of xx% during the foreseeable timeframe 2019-2029.

Request Sample Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=B&rep_id=19364

Market segments and sub-segments

The regional analysis covers:

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request For Discount On This Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=D&rep_id=19364

The Stem Cell Assay market report answers some of the important questions, including:

The report provides the following data:

Buy reports at discount prices!!!

Request For Discount On This Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=D&rep_id=19364

The Stem Cell Assay market report presents accurate and up-to-date insights regarding the Stem Cell Assay market from trusted suppliers, service providers, and value chain partners via extensive primary and secondary research. The information regarding each market vendor includes company background, main market insight, SWOT analysis, sales, revenue, pricing and gross margin, and market share.

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The companys exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMRs experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact

Mr. Rohit BhiseyTransparency Market ResearchState Tower90 State Street,Suite 700,Albany, NY 12207United StatesTel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.com

Read more:
Stem Cell Assay Market expected to Witness a Sustainable Growth over 2016 2024 Dagoretti News - Dagoretti News